Print Page   |   Sign In   |   Create a Profile
News & Press: Industry News

Amblyotech Acquires World-Wide Rights to a Novel Treatment for Amblyopia from McGill University

Monday, October 14, 2013   (0 Comments)
Posted by: Angela King
Share |

October 14, 2013 – (Atlanta) Amblyotech, LLC. (Atlanta, GA) and McGill University (Montreal, Canada) are pleased to announce the execution of a license agreement for the world-wide rights to a novel electronic application for the treatment of Amblyopia. Invented by Dr. Robert Hess, a Professor at McGill University and Director of the McGill Vision Research Unit, this treatment is a breakthrough for individuals who suffer from this ocular condition.

“This technology is a patented electronic application that, when used with a smartphone or tablet, dramatically improves the visual acuity of individuals who have Amblyopia, also known as lazy eye. Amblyopia affects up to 3% of children internationally and, if unsuccessfully treated, is a leading cause of blindness in adults. We are pleased to partner with McGill University to bring this technology to market to fulfill this unmet medical need,” stated Joseph Koziak, CEO of Amblyotech.

“McGill University has a proud history of innovation and product development in numerous fields, especially the life sciences,” stated Dr. Rose Goldstein, McGill’s Vice-Principal (Research and International Relations). “It is our pleasure to announce our partnership with Joseph Koziak, Robert Derricotte, and Amblyotech for the development of the Amblyopia technology and future opportunities.”

“Amblyotech, LLC. will be actively commercializing this technology world-wide starting with clinical trials here in Atlanta, Georgia, and throughout the U.S., which we hope to start in early 2014,” stated Robert Derricotte, COO of Amblyotech, LLC.

About Amblyotech LLC.
Amblyotech LLC was founded by Joseph Koziak and Robert Derricotte to develop and commercialize novel ocular treatments using applications designed for smartphones and tablet platforms. The company plans on building a platform of ocular technologies which are clinically proven to improve visual acuity and quality of life.

About McGill University
Founded in Montreal, Quebec, in 1821, McGill is a leading Canadian post-secondary institution. It has two campuses, 11 faculties, 11 professional schools, 300 programs of study and some 39,000 students, including 9,300 graduate students. McGill attracts students from over 150 countries around the world, with more than 8,200 international students making up 20 per cent of the student body.

For more information contact:
Joseph Koziak
CEO, Amblyotech LLC.
Ph. 770 366 6229

more Calendar

Boehringer-Ingelheim Industry Tour

Member Benefits Webinar

Membership Software Powered by YourMembership  ::  Legal